THANK YOU JEN. AHEAD OF TOMORROW’S PEACE SUMMIT, LOUISVILLE’S JEWISH COMMUNITY TOOK SOME TIME TODAY TO REFLECT AND REMEMBER. EARLIER TODAY, DOZENS OF KITES FLEW ABOVE THE JEWISH HERITAGE FUND CAMPUS ...
Wind, or the initial lack thereof, didn’t stop the Lincoln City Fall Kite Festival on Saturday afternoon. Over 50 kite performers and a few hundred audience members flocked to the beach to watch or ...
Mattel has partnered with The Pinkfong Company to reintroduce Pingu to audiences in Korea, with the latter exclusively distributing content from the 1990s and 2000s in the market. “Pingu is one of the ...
The Kite Loft's 47th annual Sunfest Kite Festival will take place in Ocean City, Maryland, from September 18-21, 2025. The festival will feature a variety of uniquely shaped kites, including dragons, ...
Earlier this month, Kite Realty Group Trust CEO John A. Kite sold 50,000 common shares of the company on September 3, 2025, amounting to US$1.13 million, following the release of the company’s ...
NUMBERS. GOOD LUCK. NOW YOU MIGHT WANT TO KEEP YOUR EYES TO THE SKIES. OF COURSE, MILWAUKEE’S LAKEFRONT THIS MORNING. VAN MCNEIL JOINS US LIVE FROM VETERANS PARK, WHERE THE FRANK MORRIS INTERNATIONAL ...
Santa Monica-based Kite, a Gilead company, agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. “In vivo therapy is ...
The round, co-led by General Catalyst and PayPal Ventures, brings the San Francisco-based startup’s cumulative funding to $33 million, according to an emailed announcement on Tuesday. Formerly known ...
Decentralized AI infrastructure provider Kite AI raised $18 million in its Series A funding round led by PayPal Ventures, bringing total cumulative funding to $33 million. According to an announcement ...
AT SIX. AND NEW AT SIX. A KITESURFER RESCUED OFF GRAVES LIGHT AND A CHANCE ENCOUNTER SAVED HIS LIFE. LET’S GET TO NEWSCENTER 5 JOHN ATWATER. HE SPOKE WITH HIM. HE JOINS US LIVE FROM EAST BOSTON RIGHT ...
Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. Integrating Interius into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback